Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 2, 2013, Pages 397-406

  Raleigh, M D ^a   Pravetoni, M ^a,b,c   Harris, A C ^b,c   Birnbaum, A K ^d   Pentel, P R ^a,b,c  

^a Departments of Pharmacology and Medicine   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c Department of Experimental and Clinical Pharmacology ^*  (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; DRUG ANTIBODY; DRUG METABOLITE; DRUGS USED IN THE TREATMENT OF ADDICTION; KEYHOLE LIMPET HEMOCYANIN; KEYHOLE LIMPET HEMOCYANIN VACCINE; MORPHINE; MORPHINE 6 ACETATE; UNCLASSIFIED DRUG; VACCINE;

ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RETENTION; DRUG SELECTIVITY; HEROIN DEPENDENCE; LOCOMOTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPEAT PROCEDURE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; BRAIN; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMOCYANIN; HEROIN; INJECTIONS, INTRAVENOUS; MALE; MORPHINE; MORPHINE DERIVATIVES; MOTOR ACTIVITY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TISSUE DISTRIBUTION; VACCINES, CONJUGATE;

EID: 84872728429     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.201194     Document Type: Article

References (41)

1. Andersen JM, Ripel A, Boix F, Normann PT, and Mørland J (2009) Increased locomotor activity induced by heroin in mice: pharmacokinetic demonstration of heroin acting as a prodrug for the mediator 6-monoacetylmorphine in vivo. J Pharmacol Exp Ther 331:153-161.
2. Anton B and Leff P (2006) A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 24:3232-3240.
3. Antonilli L, Petecchia E, Caprioli D, Badiani A, and Nencini P (2005) Effect of repeated administrations of heroin, naltrexone, methadone, and alcohol on morphine glucuronidation in the rat. Psychopharmacology (Berl) 182:58-64. (Pubitemid 41400862)
4. Bahar FG, Ohura K, Ogihara T, and Imai T (2012) Species difference of esterase expression and hydrolase activity in plasma. J Pharm Sci 101:3979-39878.
5. Bazin-Redureau MI, Renard CB, and Scherrmann JM (1997) Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat. J Pharm Pharmacol 49:277-281. (Pubitemid 27197013)
6. Bonese KF, Wainer BH, Fitch FW, Rothberg RM, and Schuster CR (1974) Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 252:708-710.
7. Carrera MR, Ashley JA, Wirsching P, Koob GF, and Janda KD (2001) A secondgeneration vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci USA 98:1988-1992. (Pubitemid 32165610)
8. Comer SD, Collins ED, MacArthur RB, and Fischman MW (1999) Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Psychopharmacology (Berl) 143:327-3378.
9. Cornish KE, Harris AC, LeSage MG, Keyler DE, Burroughs D, Earley C, and Pentel PR (2011) Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy. Int Immunopharmacol 11:1809-1815.
10. Fiellin DA, Friedland GH, and Gourevitch MN (2006) Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Iinfect Dis 43 (Suppl 4): S173-177. (Pubitemid 44901884)
11. Girardin F, Rentsch KM, Schwab MA, Maggiorini M, Pauli-Magnus C, Kullak- Ublick GA, Meier PJ, and Fattinger K (2003) Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. Clin Pharmacol Ther 74: 341-352. (Pubitemid 37222855)
12. Haney M, Gunderson EW, Jiang H, Collins ED, and Foltin RW (2010) Cocainespecific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 67:59-65.
13. Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA, Tashkin DP, Reus VI, Akhavain RC, and Fahim RE, et al. (2011) Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 89:392-399.
14. Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, and Simon EJ (1983) Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci 33 (Suppl 1):773-776. (Pubitemid 14202648)
15. Jones JM, Raleigh MD, Pentel PR, Harmon TM, Keyler DE, Remmel RP, and Birnbaum AK (2013) Stability of heroin, 6-monoacteylmorphine, and morphine in biological samples and validation of an LC-MS assay for delayed analyses of pharmacokinetic samples in rats. J Pharm Biomed Anal 74:291-297.
16. Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, and Fox BS (2000) Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat selfadministration model. Psychopharmacology (Berl) 148:251-262. (Pubitemid 30136732)
17. Klous MG, Van den Brink W, Van Ree JM, and Beijnen JH (2005) Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients. Drug Alcohol Depend 80:283-295. (Pubitemid 41660849)
18. Krupitsky E, Zvartau E, and Woody G (2010) Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep 12:448-453.
19. Li QQ, Luo YX, Sun CY, Xue YX, Zhu WL, Shi HS, Zhai HF, Shi J, and Lu L (2011) A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats. J Neurochem 119:1271-1281.
20. Lobmaier P, GossopM, Waal H, and Bramness J (2010) The pharmacological treatment of opioid addiction - a clinical perspective. Eur J Clin Pharmacol 66:537-545.
21. Martell BA, Mitchell E, Poling J, Gonsai K, and Kosten TR (2005) Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 58: 158-164. (Pubitemid 41008133)
22. McCallum SE, Caggiula AR, Epstein LH, Saylor S, Ploskina T, and Sved AF (1999) Mecamylamine blocks the development of tolerance to nicotine in rats: implications for the mechanisms of tolerance. Psychopharmacology (Berl) 141:332-3378.
23. Mendelson J, Flower K, Pletcher MJ, and Galloway GP (2008) Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine. Exp Clin Psychopharmacol 16:435-441.
24. Minagawa T, Kohno Y, Suwa T, and Tsuji A (1995) Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases. Biochem Pharmacol 49:1361-1365.
25. O'Malley SS, Krishnan-Sarin S, Farren C, and O'Connor PG (2000) Naltrexoneinduced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects. J Clin Psychopharmacol 20:69-76. (Pubitemid 30056356)
26. Pacifici R, di Carlo S, Bacosi A, Pichini S, and Zuccaro P (2000) Pharmacokinetics and cytokine production in heroin and morphine-treated mice. Int J Immunopharmacol 22:603-614. (Pubitemid 30320800)
27. Pravetoni M, Keyler DE, Raleigh MD, Harris AC, Lesage MG, Mattson CK, Pettersson S, and Pentel PR (2011) Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochem Pharmacol 81: 1164-1170.
28. Pravetoni M, Le Naour M, Harmon TM, Tucker AM, Portoghese PS, and Pentel PR (2012a) An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. J Pharmacol Exp Ther 341:225-232.
29. Pravetoni M, Raleigh MD, Le Naour M, Tucker AM, Harmon TM, Jones JM, Birnbaum AK, Portoghese PS, and Pentel PR (2012b) Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine 30:4617-4624.
30. Roiko SA, Harris AC, Keyler DE, Lesage MG, Zhang Y, and Pentel PR (2008) Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats. J Pharmacol Exp Ther 325:985-993. (Pubitemid 351724343)
31. Rook EJ, Huitema AD, van den Brink W, van Ree JM, and Beijnen JH (2006) Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol 1:109-1178.
32. Salmon AY, Goren Z, Avissar Y, and Soreq H (1999) Human erythrocyte but not brain acetylcholinesterase hydrolyses heroin to morphine. Clin Exp Pharmacol Physiol 26:596-600. (Pubitemid 29369917)
33. Satoskar SD, Keyler DE, LeSage MG, Raphael DE, Ross CA, and Pentel PR (2003) Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int Immunopharmacol 3:957-970. (Pubitemid 36694866)
34. Selley DE, Cao CC, Sexton T, Schwegel JA, Martin TJ, and Childers SR (2001) mu Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compare with morphine. Biochem Pharmacol 62:447-455. (Pubitemid 32607727)
35. Stowe GN, Vendruscolo LF, Edwards S, Schlosburg JE, Misra KK, Schulteis G, Mayorov AV, Zakhari JS, Koob GF, and Janda KD (2011) A vaccine strategy that induces protective immunity against heroin. J Med Chem 54:5195-5204.
36. Swerdlow NR, Vaccarino FJ, and Koob GF (1985) Effects of naloxone on heroin-, amphetamine- and caffeine-stimulated locomotor activity in the rat. Pharmacol Biochem Behav 23:499-501. (Pubitemid 16256923)
37. Tang YL and Hao W (2007) Improving drug addiction treatment in China. Addiction 102:1057-1063. (Pubitemid 46918669)
38. Tang YL, Zhao D, Zhao C, and Cubells JF (2006) Opiate addiction in China: current situation and treatments. Addiction 101:657-665.
39. Umans JG and Inturrisi CE (1982) Heroin: analgesia, toxicity and disposition in the mouse. Eur J Pharmacol 85:317-323. (Pubitemid 13202115)
40. Vindenes V, Ripel A, Handal M, Boix F, and Mørland J (2009) Interactions between morphine and the morphine-glucuronides measured by conditioned place preference and locomotor activity. Pharmacol Biochem Behav 93:1-9.
41. Way EL, Kemp JW, Young JM, and Grassetti DR (1960) The pharmacologic effects of heroin in relationship to its rate of biotransformation. J Pharmacol Exp Ther 129: 144-154.